May. 21 at 2:59 AM
$ATHE Link to Spotify interview shared on X today.
Q @ 31:06: “In terms of, whether it’s longer-term or otherwise, partnering, or yeah a commercial partner in terms of 434 - you know, obviously phase 3 trials aren’t cheap - how does that sort of look in terms of funding or partnering?”
CEO: “Yeah we’ve had a tremendous amount of interest - inbound interest - in this program and in this molecule. I think uh, from a purely commercial standpoint, given the significant unmet need for MSA patients translates into there are no approved therapies, and because it is an orphan disease that gets preferential pricing, there’s a big commercial opportunity. So we’ve had a lot of interest from big pharmaceutical companies, from mid-size pharmaceutical companies, um, so yeah I think that’s a very fertile ground and something we’re very actively looking at.”
